Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 14/20 | 0.68 |
| ▸ | EHMT1 | Q9H9B1 | 9/20 | 0.68 |
| ▸ | KDM1A | O60341 | 4/20 | 0.61 |
| ▸ | WHR1 | P49842 | 1/20 | 0.54 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382142 | 0.81 | EHMT1 (1.00) | EHMT2EHMT1KDM1ARCOR1HDAC1 | |
| SCHEMBL23260478 | 0.81 | EHMT1 (1.00) | EHMT2EHMT1KDM1ARCOR1HDAC1 | |
| SCHEMBL1427723 | 0.76 | EHMT2 (0.75) | EHMT2KDM1AWHR1RCOR1 | |
| SCHEMBL27224034 | 0.76 | GBA1 (0.54) | EHMT2KDM1ARCOR1SLC2A1 | |
| SCHEMBL15714811 | 0.76 | EHMT2 (1.00) | EHMT2KDM1ARCOR1 | |
| SCHEMBL11735120 | 0.76 | CASP6 (0.84) | CASP6SLC2A1 | |
| SCHEMBL23261502 | 0.75 | EHMT2 (0.62) | EHMT2EHMT1KDM1AWHR1RCOR1 | |
| Hydrochloric Acid SCHEMBL8905933 | 0.75 | EHMT2 (0.54) | EHMT2KDM1AWHR1RCOR1SLC2A1 | |
| SCHEMBL14256578 | 0.75 | MERTK (0.55) | EHMT2KDM1ASLC2A1 | |
| SCHEMBL1427783 | 0.74 | EHMT2 (0.60) | EHMT2EHMT1KDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| WO-2021076617-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | YTHDF1, YTHDF3, YTHDF2 | EHMT2 231/4885EHMT1 296/4885KDM1A 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.